New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePEG-MGF vs AICAR

PEG-MGF vs AICAR

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
PEG-MGF
Anti-Aging & LongevityFat Loss & Metabolic
AICAR
Summary
PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
AICAR is a cell-permeable AMP analog that activates AMPK (AMP-activated protein kinase) — the master metabolic switch that triggers fat burning, mitochondrial biogenesis, and adaptations normally only achieved through exercise. It has been called the 'exercise in a pill' compound.
Half-Life
~3 days (due to PEGylation)
~2–3 hours
Admin Route
SubQ
SubQ, IV
Research
Typical Dose
200–400 mcg
25–50 mg
Frequency
2–3x per week
3–5 times per week
Key Benefits
  • Extended half-life (~3 days) vs native MGF (minutes)
  • Systemic muscle satellite cell activation via subcutaneous injection
  • Promotes muscle fiber repair and hypertrophy throughout the body
  • Enhanced recovery from intense training or muscle injury
  • Synergistic with IGF-1 LR3 and growth hormone peptides
  • Useful in sarcopenia, post-injury recovery, and athletic performance
  • Single injection provides multi-day anabolic signaling
  • AMPK activation mimics aerobic exercise adaptations
  • Increased fat oxidation and endurance
  • Mitochondrial biogenesis (PGC-1alpha)
  • Improved insulin sensitivity and glucose metabolism
  • Anti-inflammatory effects
  • Potential cardiac protection during ischemia
  • Synergistic with actual exercise training
  • Reduces hepatic glucose production
Side Effects
  • Water retention and localized swelling
  • Potential hypoglycemia at high doses
  • Theoretical cancer growth risk (growth factor)
  • Injection site reactions
  • +1 more
  • Hypoglycemia risk
  • Lactic acidosis at high doses (animal data)
  • Injection site irritation
Stacks With